by Clinical Neuropsychologist Online | Thursday, April 4, 2024 | Dementia
Abstract INTRODUCTION Screening for Alzheimer’s disease neuropathologic change (ADNC) in individuals with atypical presentations is challenging but essential for clinical management. We trained automatic speech-based classifiers to distinguish frontotemporal...
by Clinical Neuropsychologist Online | Thursday, April 4, 2024 | Neurorehabilitation
Rehabilitation Psychology, Vol 70(1), Feb 2025, 75-83; doi:10.1037/rep0000561Purpose: This study examines (a) whether disability registration has anticipatory, immediate, and delayed effects on depressive symptoms and (b) how these effects differ by gender. Research...
by Clinical Neuropsychologist Online | Wednesday, April 3, 2024 | Neuropsychology (general)
Volume 38, Issue 6, August 2024. If you do not see content above, kindly GO TO SOURCE. Not all publishers encode content in a way that enables republishing at Neuro.vip. This post is Copyright: Erin Logue Robin C. Hilsabeck Esther Melamed Dell Medical School, The...
by Clinical Neuropsychologist Online | Wednesday, April 3, 2024 | Dementia
Dementia, Volume 23, Issue 4, Page 525-549, May 2024. BackgroundDementia disproportionately affects women including persons living with dementia and caregivers. Person-centered care, rather than disease-focused, is recommended to improve care for affected persons...
by Clinical Neuropsychologist Online | Wednesday, April 3, 2024 | Dementia
Abstract INTRODUCTION Aducanumab selectively targets aggregated forms of amyloid beta (Aβ), a neuropathological hallmark of Alzheimer’s disease (AD). METHODS PRIME was a Phase 1b, double-blind, randomized clinical trial of aducanumab. During the 12-month...
